Nonalcoholic fatty liver disease and cardiovascular disease risk.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is prevalent in people with the metabolic syndrome and type 2 diabetes. Evidence is now accumulating that NAFLD is associated with obesity and diabetes and may serve as a predictor of cardiovascular disease. Although at present, treatment of the individual risk factors pertinent to NAFLD is advocated, novel therapies are emerging that may target steatosis and/or inflammation, thus ameliorating the overall cardiovascular disease risk. Long-term outcome studies need to establish whether treatment of NAFLD (and in particular which therapy) will affect the long-term outcome.

• Authors: Roger K Schindhelm, Michaela Diamant, Robert J Heine
• Journal: Current diabetes reports (Curr Diab Rep) Vol. 7 Issue 3 Pg. 181-7 (Jun 2007) ISSN: 1534-4827 [Print] United States
• PMID: 17547835 (Publication Type: Journal Article, Review)

Topics

• Cardiovascular Diseases (complications, enzymology, epidemiology)
• Diabetes Mellitus, Type 2 (complications, enzymology, epidemiology)
• Fatty Liver (complications, drug therapy, enzymology, epidemiology)
• Female
• Humans
• Male
• Obesity (complications, epidemiology)